Security record · archived quarter
GMAB
Genmab A/S · Healthcare · Biotechnology
1Tracked holders
0Δ holders
18.12KShares held
$653,093Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 18.12K | $653,093 | n/a | n/a |
| Q2 2026 | 80 | +8 | 51.55M | $1.41B | +9 | −1 |
| Q1 2026 | 73 | -4 | 45.85M | $1.27B | +5 | −9 |
| Q4 2025 | 77 | 0 | 41.23M | $1.28B | n/a | n/a |
| Q3 2025 | 13 | -2 | 16.25M | $498.26M | n/a | −2 |
| Q2 2025 | 12 | +1 | 18.14M | $374.87M | +1 | n/a |
| Q1 2025 | 9 | 0 | 13.96M | $273.33M | n/a | n/a |
| Q4 2024 | 9 | 0 | 8.94M | $186.52M | +1 | −1 |
| Q3 2024 | 9 | -1 | 7.29M | $175.79M | n/a | −1 |
| Q2 2024 | 10 | n/a | 6.88M | $172.85M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 18.12K | +21.4% | $653,093 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 25.36K shares, $6.69M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API